2026-06-29

Copper volume spike - 39.5× the 20-day average (32,837 vs 830 avg)

Platinum volume spike - 2161.3× the 20-day average (12,860 vs 5 avg)

Silver volume spike - 612.9× the 20-day average (30,247 vs 49 avg)

Gold volume spike - 74.5× the 20-day average (103,093 vs 1,384 avg)

Cotton bull 7.0% vs prior close ($71.66 → $76.66)

OSINT: Israel Signals Long-Term Military Presence in Lebanon

OSINT: Russia Faces Widespread Fuel Shortages Amid Growing War Discontent

OSINT: Europe bans gasoline for aviation, tightening fuel supply

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Trump Announces Plan for Public Golf Course in Washington D.C.

Sugar No. 11 bull 5.9% vs prior close ($13.98 → $14.80)

30Y Treasury Bond volume spike - 2.2× the 20-day average (293,621 vs 130,792 avg)

ETH open interest +207.5% - OI surge

BTC open interest +77.3% - OI surge

SOL open interest +235.1% - OI surge

ETH open interest -67.9% - OI collapse

BTC open interest -43.9% - OI collapse

SOL open interest +32.2% - OI surge

BTC open interest -69.6% - OI collapse

SOL open interest -61.4% - OI collapse

ETH open interest +208.3% - OI surge

SOL open interest -24.3% - OI collapse

ETH open interest +207.1% - OI surge

BTC open interest -45.2% - OI collapse

OSINT: SVB reports $67B crypto-backed lending in Q1 2026, rebound from crises

SOL DEX volume/liquidity ratio elevated (1.45x): on-chain trade volume 1.45x liquidity

OSINT: Top 10 DeFi protocols generate >80% of holder revenue in past week

OSINT: AI-linked sectors see sharp job losses, avg 11k per month

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

ETH RSI 27.8 - oversold (crossed below 30)

OSINT: Solana Launches FlashTrade V2 Perps with 50ms Execution and Gasless Trading

ETH DEX volume/liquidity ratio elevated (0.50x): on-chain trade volume 0.50x liquidity

SOL DEX volume/liquidity ratio elevated (1.55x): on-chain trade volume 1.55x liquidity

ETH RSI 21.6 - oversold (crossed below 30)

SOL DEX volume/liquidity ratio elevated (1.10x): on-chain trade volume 1.10x liquidity

ETH RSI 20.9 - oversold (crossed below 30)

Phase 3 trial terminated early - BRISTOL A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Anti

Phase 3 trial terminated early - BIOGEN An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Phase 3 trial terminated early - BIOGEN A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Ho

Phase 3 trial terminated early - BIOGEN Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2

Phase 3 trial terminated early - AMGEN TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel

Phase 3 trial terminated early - Medtronic Radial Reload Laparoscopic LAR Case Series

Phase 3 trial terminated early - Merck Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized

Phase 3 trial terminated early - Merck Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density L

Phase 3 trial terminated early - Merck A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant

Phase 3 trial terminated early - Merck An Open-label Study to Identify Molecular Markers of Steroid Resistance

Phase 3 trial terminated early - PFIZER Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Mo

Phase 3 trial terminated early - PFIZER Neuromuscular Changes In Small For Gestational Age Children During Somatropin Th

Phase 3 trial terminated early - PFIZER A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease P

Phase 3 trial terminated early - PFIZER Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment O

Phase 3 trial terminated early - ABBOTT Effect of Enteral Nutrition Support for Critically Ill Patients

Phase 3 trial terminated early - ABBOTT Study of Blood Concentrations and Physiologic Effects of Levosimendan Given Duri

Phase 3 trial terminated early - GILEAD Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitab

Arcosa, Inc. search volume spiked +100 pts - unusual interest

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

OSINT: SVB reports $67B crypto-backed lending in Q1 2026, rebound from crises

OSINT: Ukraine equips M113 APCs with ‘hamster ball’ cage armor to counter drones

SOUTHERN CO search volume spiked +27 pts - unusual interest

OSINT: AI-linked sectors see sharp job losses, avg 11k per month

BLACK HILLS CORP /SD/ search volume spiked +100 pts - unusual interest

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

Parker-Hannifin Corp search volume spiked +100 pts - unusual interest

Birkenstock Holding plc search volume spiked +100 pts - unusual interest

OSINT: Solana Launches FlashTrade V2 Perps with 50ms Execution and Gasless Trading

Arcosa, Inc. search volume spiked +100 pts - unusual interest

SOUTHERN CO search volume spiked +27 pts - unusual interest

BLACK HILLS CORP /SD/ search volume spiked +100 pts - unusual interest

Parker-Hannifin Corp search volume spiked +100 pts - unusual interest

Q4-2025: Missed consensus by 17.6% - EPS $-0.58 vs $-0.493 estimate

Q1-2026: Beat consensus by 11.8% - EPS $-0.09 vs $-0.102 estimate

Q3-2025: Beat consensus by 11.8% - EPS $-0.09 vs $-0.102 estimate

Q1-2026: Beat consensus by 7.0% - EPS $-0.12 vs $-0.129 estimate

Q2-2025: Beat consensus by 345.5% - EPS $0.45 vs $0.101 estimate

Q3-2025: Beat consensus by 98.4% - EPS $1.72 vs $0.867 estimate

Q3-2024: Missed consensus by 9.5% - EPS $-38.19 vs $-34.884 estimate

Q1-2025: Missed consensus by 71.6% - EPS $-6.65 vs $-3.876 estimate

Q4-2025: Missed consensus by 48.3% - EPS $0.03 vs $0.058 estimate

Q4-2025: Missed consensus by 30.7% - EPS $-0.16 vs $-0.1224 estimate

Q4-2024: Missed consensus by 78.3% - EPS $-6 vs $-3.366 estimate

Q1-2025: Missed consensus by 105.0% - EPS $-3.45 vs $-1.683 estimate

Q2-2018: Missed consensus by 71.6% - EPS $-975 vs $-568.125 estimate

Q4-2026: Missed consensus by 58.8% - EPS $14 vs $34.007 estimate

Q1-2024: Missed consensus by 241.6% - EPS $-26 vs $18.36 estimate

Q2-2024: Beat consensus by 34.6% - EPS $-16 vs $-24.48 estimate

Q3-2024: Beat consensus by 22.7% - EPS $-15.77 vs $-20.4 estimate

Q4-2023: Missed consensus by 394.1% - EPS $-5.4 vs $1.836 estimate

Q1-2024: Missed consensus by 128.8% - EPS $-12.6 vs $-5.508 estimate

Q1-2026: Missed consensus by 233.9% - EPS $-3.36 vs $-1.0064 estimate

Q2-2025: Beat consensus by 27.8% - EPS $-1.12 vs $-1.5504 estimate

Q3-2025: Beat consensus by 16.7% - EPS $-1.36 vs $-1.632 estimate

Q4-2025: Beat consensus by 87.3% - EPS $1.9364 vs $1.0336 estimate

Q1-2023: Missed consensus by 128.8% - EPS $-1.05 vs $-0.459 estimate

Q2-2023: Missed consensus by 279.1% - EPS $-2.9 vs $-0.765 estimate

Q4-2023: Beat consensus by 25.7% - EPS $-4.7 vs $-6.324 estimate

Q1-2023: Missed consensus by 46.4% - EPS $-10.9 vs $-7.446 estimate

Q2-2023: Missed consensus by 19.6% - EPS $-11.1 vs $-9.282 estimate

Q3-2023: Beat consensus by 179.2% - EPS $8 vs $-10.098 estimate

Q3-2022: Beat consensus by 24.8% - EPS $-0.23 vs $-0.306 estimate

Q4-2025: Missed consensus by 105.0% - EPS $-0.02 vs $0.399 estimate

Q1-2026: Beat consensus by 7.4% - EPS $0.68 vs $0.6334 estimate

Q4-2025: Missed consensus by 6.9% - EPS $0.38 vs $0.408 estimate

Q2-2025: Beat consensus by 29.4% - EPS $-0.06 vs $-0.085 estimate

Q4-2025: Beat consensus by 96.1% - EPS $-0.002 vs $-0.051 estimate

Q3-2025: Missed consensus by 123.1% - EPS $-0.29 vs $-0.13 estimate

Q3-2025: Beat consensus by 8.5% - EPS $1.9 vs $1.751 estimate

Q1-2025: Missed consensus by 96.1% - EPS $-0.18 vs $-0.0918 estimate

Q4-2025: Missed consensus by 19.4% - EPS $0.19 vs $0.2357 estimate

Q3-2025: Beat consensus by 11.8% - EPS $0.303 vs $0.271 estimate

Q3-2025: Missed consensus by 80.9% - EPS $-0.123 vs $-0.068 estimate

Q1-2026: Beat consensus by 21.6% - EPS $-0.04 vs $-0.051 estimate

Q2-2026: Missed consensus by 166.9% - EPS $-0.98 vs $-0.3672 estimate

Q1-2026: Beat consensus by 24.3% - EPS $0.21 vs $0.169 estimate

Q4-2025: Missed consensus by 22.9% - EPS $0.3 vs $0.389 estimate

Q3-2025: Beat consensus by 17.6% - EPS $0.18 vs $0.153 estimate

Q2-2025: Beat consensus by 89.5% - EPS $0.29 vs $0.153 estimate

Q1-2026: Beat consensus by 56.8% - EPS $-0.032 vs $-0.074 estimate

Q1-2026: Beat consensus by 29.7% - EPS $-0.43 vs $-0.612 estimate

Q2-2008: Missed consensus by 194.1% - EPS $-30 vs $-10.2 estimate

Q3-2008: Missed consensus by 96.1% - EPS $-30 vs $-15.3 estimate

Q4-2007: Beat consensus by 16.0% - EPS $-15 vs $-17.85 estimate

Q1-2008: Beat consensus by 51.0% - EPS $-10 vs $-20.4 estimate

Q3-2025: Beat consensus by 18.5% - EPS $1.03 vs $0.869 estimate

Q1-2026: Missed consensus by 7.3% - EPS $0.37 vs $0.399 estimate

Q4-2024: Beat consensus by 6.9% - EPS $-0.19 vs $-0.204 estimate

Q3-2025: Beat consensus by 41.2% - EPS $-0.18 vs $-0.306 estimate

Q1-2026: Missed consensus by 18.2% - EPS $-0.53002 vs $-0.4484 estimate

Q4-2025: Missed consensus by 914.0% - EPS $-1.60008 vs $-0.1578 estimate

Q1-2026: Beat consensus by 24.6% - EPS $-1.23 vs $-1.632 estimate

Q3-2025: Beat consensus by 45.5% - EPS $-2 vs $-3.672 estimate

Q4-2025: Beat consensus by 70.6% - EPS $-1.2 vs $-4.08 estimate

Q2-2025: Missed consensus by 22.5% - EPS $-4 vs $-3.264 estimate

Q3-2025: Beat consensus by 29.3% - EPS $2.8 vs $2.166 estimate

Q2-2025: Missed consensus by 10.7% - EPS $-0.08 vs $-0.0723 estimate

Q3-2025: Missed consensus by 41.2% - EPS $0.03 vs $0.051 estimate

Q2-2025: Beat consensus by 5.9% - EPS $0.09 vs $0.085 estimate

Q1-2026: Missed consensus by 66.7% - EPS $-0.17 vs $-0.102 estimate

Q1-2026: Beat consensus by 14.4% - EPS $-0.16 vs $-0.187 estimate

Q3-2025: Beat consensus by 73.9% - EPS $-0.12 vs $-0.459 estimate

Q1-2026: Beat consensus by 9.1% - EPS $30.29771 vs $27.772 estimate

Q4-2024: Beat consensus by 45.1% - EPS $-0.14 vs $-0.255 estimate

Q3-2026: Beat consensus by 55.4% - EPS $-0.0683 vs $-0.153 estimate

Q1-2026: Beat consensus by 9.1% - EPS $1.24 vs $1.137 estimate

Q4-2025: Missed consensus by 48.2% - EPS $0.48 vs $0.927 estimate

Q1-2026: Missed consensus by 291.4% - EPS $-1.85 vs $-0.4727 estimate

Q4-2025: Beat consensus by 42.9% - EPS $0.34 vs $0.238 estimate

Q3-2025: Missed consensus by 14.6% - EPS $-0.94 vs $-0.82 estimate

Q3-1997: Missed consensus by 217.6% - EPS $-0.78 vs $0.663 estimate

Q3-2023: Beat consensus by 42.2% - EPS $-39600 vs $-68544 estimate

Q4-2023: Missed consensus by 19.3% - EPS $-80700 vs $-67626 estimate

Q3-2025: Beat consensus by 71.2% - EPS $-8.85 vs $-30.753 estimate

Q4-2025: Missed consensus by 101.4% - EPS $-60.1 vs $-29.835 estimate

Q1-2026: Beat consensus by 73.9% - EPS $-0.12 vs $-0.459 estimate

Q1-2022: Missed consensus by 243.1% - EPS $-1.4 vs $-0.408 estimate

Q1-2026: Beat consensus by 16.8% - EPS $0.16 vs $0.137 estimate

Q1-2026: Missed consensus by 167.7% - EPS $-3.38 vs $-1.2625 estimate

Q2-2026: Beat consensus by 47.7% - EPS $0.26 vs $0.176 estimate

Q3-2025: Missed consensus by 8.5% - EPS $0.14 vs $0.153 estimate

Q4-2025: Beat consensus by 9.9% - EPS $2.53 vs $2.303 estimate

Q1-2026: Beat consensus by 41.2% - EPS $-0.06 vs $-0.102 estimate

Q1-2024: Missed consensus by 16.2% - EPS $-256 vs $-220.32 estimate

Q4-2023: Missed consensus by 30.7% - EPS $-256 vs $-195.84 estimate

Q2-2024: Beat consensus by 33.5% - EPS $-152 vs $-228.48 estimate

Q3-2025: Beat consensus by 87.6% - EPS $-0.01 vs $-0.0808 estimate

Q3-2025: Beat consensus by 135.3% - EPS $0.24 vs $0.102 estimate

Q1-2026: Beat consensus by 47.1% - EPS $-0.35 vs $-0.662 estimate

Q4-2025: Beat consensus by 45.8% - EPS $0.14 vs $0.096 estimate

Q2-2025: Missed consensus by 17.5% - EPS $0.203 vs $0.246 estimate

Q1-2021: Beat consensus by 100.0% - EPS $0 vs $-5.712 estimate

Q4-2021: Beat consensus by 438.5% - EPS $64.05 vs $-18.921 estimate

Q3-2025: Beat consensus by 14.7% - EPS $-0.11 vs $-0.129 estimate

Q2-2025: Beat consensus by 156.0% - EPS $0.8 vs $-1.428 estimate

Q3-2024: Beat consensus by 15.5% - EPS $10.6 vs $9.18 estimate

Q1-2025: Missed consensus by 1272.5% - EPS $-2.8 vs $-0.204 estimate

Q2-2025: Missed consensus by 9.5% - EPS $1.1 vs $1.216 estimate

Q1-2025: Beat consensus by 13.8% - EPS $-382.5 vs $-443.7 estimate

Q3-2025: Beat consensus by 140.5% - EPS $20.84 vs $-51.51 estimate

Q2-2025: Beat consensus by 39.2% - EPS $-79.73 vs $-131.07 estimate

Q1-2026: Beat consensus by 18.5% - EPS $-1.58 vs $-1.938 estimate

Q3-2026: Beat consensus by 27.3% - EPS $-0.63 vs $-0.867 estimate

Q4-2025: Beat consensus by 18.1% - EPS $-1.88 vs $-2.295 estimate

Q2-2025: Beat consensus by 17.0% - EPS $0.39 vs $0.3333 estimate

Q4-2026: Beat consensus by 74.4% - EPS $-0.06 vs $-0.2346 estimate

Q4-2025: Missed consensus by 15.6% - EPS $1.55 vs $1.836 estimate

Bond issued at elevated rate 15.315% - credit-stress signal

Birkenstock Holding plc search volume spiked +100 pts - unusual interest

Arcosa, Inc. search volume spiked +100 pts - unusual interest

SOUTHERN CO search volume spiked +27 pts - unusual interest

BLACK HILLS CORP /SD/ search volume spiked +100 pts - unusual interest

Parker-Hannifin Corp search volume spiked +100 pts - unusual interest

OSINT: USAF Conducts Coronet East Exercise with KC-135 Tankers and A-10Cs

OSINT: Ukraine equips M113 APCs with ‘hamster ball’ cage armor to counter drones

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

VIX at 18.4: CAUTION territory

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

OSINT: Paraguay and Germany deadlocked 1-1, match heads to extra time

OSINT: AI-linked sectors see sharp job losses, avg 11k per month

OSINT: Mamdani Rejects Constitutional Change to Extend Presidential Eligibility